{"count": 8, "results": [{"_id": "34716862", "pmid": 34716862, "title": "Synergistic effect of metformin and vemurufenib (PLX4032) as a molecular targeted therapy in anaplastic thyroid cancer: an in vitro study.", "journal": "Mol Biol Rep", "authors": ["Durai L", "Ravindran S", "Arvind K", "Karunagaran D", "Vijayalakshmi R"], "date": "2021-11-01T00:00:00Z", "doi": "10.1007/s11033-021-06762-7", "meta_date_publication": "2021 Nov", "meta_volume": "48", "meta_issue": "11", "meta_pages": "7443-7456", "score": 50266.92, "text_hl": "Synergistic effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and vemurufenib (@CHEMICAL_Vemurafenib @CHEMICAL_MESH:D000077484 @@@PLX4032@@@) as a molecular targeted therapy in @<m>DISEASE_Thyroid_Carcinoma_Anaplastic</m> @DISEASE_MESH:D065646 @@@anaplastic thyroid cancer@@@: an in vitro study.", "citations": {"NLM": "Durai L, Ravindran S, Arvind K, Karunagaran D, Vijayalakshmi R. Synergistic effect of metformin and vemurufenib (PLX4032) as a molecular targeted therapy in anaplastic thyroid cancer: an in vitro study. Mol Biol Rep. 2021 Nov;48(11):7443-7456. PMID: 34716862", "BibTeX": "@article{34716862, title={Synergistic effect of metformin and vemurufenib (PLX4032) as a molecular targeted therapy in anaplastic thyroid cancer: an in vitro study.}, author={Durai L and Ravindran S and Arvind K and Karunagaran D and Vijayalakshmi R}, journal={Mol Biol Rep}, volume={48}, number={11}, pages={7443-7456}}"}}, {"_id": "32589349", "pmid": 32589349, "title": "Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells.", "journal": "J Biochem Mol Toxicol", "authors": ["Ozdemir Kutbay N", "Biray Avci C", "Sarer Yurekli B", "Caliskan Kurt C", "Shademan B", "Gunduz C", "Erdogan M"], "date": "2020-10-01T00:00:00Z", "doi": "10.1002/jbt.22547", "meta_date_publication": "2020 Oct", "meta_volume": "34", "meta_issue": "10", "meta_pages": "e22547", "score": 50259.117, "text_hl": "Effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and @CHEMICAL_Pioglitazone @CHEMICAL_MESH:D000077205 @@@pioglitazone@@@ combination on apoptosis and @GENE_PRKAA2 @GENE_5563 @@@AMPK@@@/@GENE_MTOR @GENE_2475 @@@mTOR@@@ signaling pathway in @SPECIES_9606 @@@human@@@ @<m>DISEASE_Thyroid_Carcinoma_Anaplastic</m> @DISEASE_MESH:D065646 @@@anaplastic thyroid cancer@@@ cells.", "citations": {"NLM": "Ozdemir Kutbay N, Biray Avci C, Sarer Yurekli B, Caliskan Kurt C, Shademan B, Gunduz C, Erdogan M. Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells. J Biochem Mol Toxicol. 2020 Oct;34(10):e22547. PMID: 32589349", "BibTeX": "@article{32589349, title={Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells.}, author={Ozdemir Kutbay N and Biray Avci C and Sarer Yurekli B and Caliskan Kurt C and Shademan B and Gunduz C and Erdogan M}, journal={J Biochem Mol Toxicol}, volume={34}, number={10}, pages={e22547}}"}}, {"_id": "32791889", "pmid": 32791889, "title": "Metformin Reduces Thyroid Cancer Tumor Growth in the Metastatic Niche of Bone by Inhibiting Osteoblastic RANKL Productions.", "journal": "Thyroid", "authors": ["Shin HS", "Sun HJ", "Whang YM", "Park YJ", "Park DJ", "Cho SW"], "date": "2021-05-01T00:00:00Z", "doi": "10.1089/thy.2019.0851", "meta_date_publication": "2021 May", "meta_volume": "31", "meta_issue": "5", "meta_pages": "760-771", "score": 50255.54, "text_hl": "Methods: The @<m>DISEASE_Thyroid_Carcinoma_Anaplastic</m> @DISEASE_MESH:D065646 @@@anaplastic thyroid cancer@@@ (@<m>DISEASE_Thyroid_Carcinoma_Anaplastic</m> @DISEASE_MESH:D065646 @@@ATC@@@) cell lines @CELLLINE_CVCL:6287 @@@FRO@@@ and @CELLLINE_CVCL:3883 @@@SW1736@@@ were used to test the antitumoral effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in vitro and in vivo. ", "citations": {"NLM": "Shin HS, Sun HJ, Whang YM, Park YJ, Park DJ, Cho SW. Metformin Reduces Thyroid Cancer Tumor Growth in the Metastatic Niche of Bone by Inhibiting Osteoblastic RANKL Productions. Thyroid. 2021 May;31(5):760-771. PMID: 32791889", "BibTeX": "@article{32791889, title={Metformin Reduces Thyroid Cancer Tumor Growth in the Metastatic Niche of Bone by Inhibiting Osteoblastic RANKL Productions.}, author={Shin HS and Sun HJ and Whang YM and Park YJ and Park DJ and Cho SW}, journal={Thyroid}, volume={31}, number={5}, pages={760-771}}"}}, {"_id": "37289199", "pmid": 37289199, "pmcid": "PMC10527034", "title": "Thyroid cancers exhibit oncogene-enhanced macropinocytosis that is restrained by IGF1R and promotes albumin-drug-conjugate response", "journal": "Clin Cancer Res", "authors": ["Hu H", "Ng TSC", "Kang M", "Scott E", "Li R", "Quintana JM", "Matvey D", "Vantaku VR", "Weissleder R", "Parangi S", "Miller MA"], "date": "2023-06-08T00:00:00Z", "doi": "10.1158/1078-0432.CCR-22-2976", "meta_date_publication": "2023 Jun 8", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50249.406, "text_hl": "@CHEMICAL_picropodophyllin @CHEMICAL_MESH:C415032 @@@AXL1717@@@ and/or @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ failed to affect bulk @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@tumor@@@ accumulation of @GENE_ALB @GENE_213 @@@albumin@@@ in @<m>DISEASE_Thyroid_Carcinoma_Anaplastic</m> @DISEASE_MESH:D065646 @@@ATC@@@ (Fig. 5E), and we investigated the disparity between monoculture and in vivo results. ", "citations": {"NLM": "Hu H, Ng TSC, Kang M, Scott E, Li R, Quintana JM, Matvey D, Vantaku VR, Weissleder R, Parangi S, Miller MA. Thyroid cancers exhibit oncogene-enhanced macropinocytosis that is restrained by IGF1R and promotes albumin-drug-conjugate response Clin Cancer Res. 2023 Jun 8;():. PMID: 37289199", "BibTeX": "@article{37289199, title={Thyroid cancers exhibit oncogene-enhanced macropinocytosis that is restrained by IGF1R and promotes albumin-drug-conjugate response}, author={Hu H and Ng TSC and Kang M and Scott E and Li R and Quintana JM and Matvey D and Vantaku VR and Weissleder R and Parangi S and Miller MA}, journal={Clin Cancer Res}}"}}, {"_id": "25683253", "pmid": 25683253, "title": "Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.", "journal": "Oncol Rep", "authors": ["Chen G", "Nicula D", "Renko K", "Derwahl M"], "date": "2015-04-01T00:00:00Z", "doi": "10.3892/or.2015.3805", "meta_date_publication": "2015 Apr", "meta_volume": "33", "meta_issue": "4", "meta_pages": "1994-2000", "score": 50066.047, "text_hl": "Synergistic anti-proliferative effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and @CHEMICAL_Sorafenib @CHEMICAL_MESH:D000077157 @@@sorafenib@@@ on growth of @<m>DISEASE_Thyroid_Carcinoma_Anaplastic</m> @DISEASE_MESH:D065646 @@@anaplastic thyroid cancer@@@ cells and their stem cells.", "citations": {"NLM": "Chen G, Nicula D, Renko K, Derwahl M. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells. Oncol Rep. 2015 Apr;33(4):1994-2000. PMID: 25683253", "BibTeX": "@article{25683253, title={Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.}, author={Chen G and Nicula D and Renko K and Derwahl M}, journal={Oncol Rep}, volume={33}, number={4}, pages={1994-2000}}"}}, {"_id": "30242671", "pmid": 30242671, "pmcid": "PMC6279666", "title": "Effects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines", "journal": "Daru", "authors": ["Nozhat Z", "Mohammadi-Yeganeh S", "Azizi F", "Zarkesh M", "Hedayati M"], "date": "2018-12-01T00:00:00Z", "doi": "10.1007/s40199-018-0208-2", "meta_date_publication": "2018 Dec", "meta_volume": "26", "meta_issue": "2", "meta_pages": "93-103", "score": 50064.617, "text_hl": "...@<m>DISEASE_Thyroid_Carcinoma_Anaplastic</m> @DISEASE_MESH:D065646 @@@Anaplastic thyroid cancer@@@ cells were treated with 0-60 mM @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ for 24, 48 and 72 h. ", "citations": {"NLM": "Nozhat Z, Mohammadi-Yeganeh S, Azizi F, Zarkesh M, Hedayati M. Effects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines Daru. 2018 Dec;26(2):93-103. PMID: 30242671", "BibTeX": "@article{30242671, title={Effects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines}, author={Nozhat Z and Mohammadi-Yeganeh S and Azizi F and Zarkesh M and Hedayati M}, journal={Daru}, volume={26}, number={2}, pages={93-103}}"}}, {"_id": "22278418", "pmid": 22278418, "title": "Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.", "journal": "J Clin Endocrinol Metab", "authors": ["Chen G", "Xu S", "Renko K", "Derwahl M"], "date": "2012-04-01T00:00:00Z", "doi": "10.1210/jc.2011-1754", "meta_date_publication": "2012 Apr", "meta_volume": "97", "meta_issue": "4", "meta_pages": "E510-20", "score": 50047.246, "text_hl": "OBJECTIVE: We investigated the effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on growth of differentiated @SPECIES_9606 @@@human@@@ thyroid cells, @<m>DISEASE_Thyroid_Carcinoma_Anaplastic</m> @DISEASE_MESH:D065646 @@@anaplastic thyroid carcinoma@@@ cells, a @CHEMICAL_Doxorubicin @CHEMICAL_MESH:D004317 @@@doxorubicin@@@-resistant @DISEASE_Thyroid_Neoplasms @DISEASE_MESH:D013964 @@@thyroid carcinoma@@@ cell line, and @DISEASE_Thyroid_Neoplasms @DISEASE_MESH:D013964 @@@thyroid cancer@@@ stem cells. ", "citations": {"NLM": "Chen G, Xu S, Renko K, Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab. 2012 Apr;97(4):E510-20. PMID: 22278418", "BibTeX": "@article{22278418, title={Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.}, author={Chen G and Xu S and Renko K and Derwahl M}, journal={J Clin Endocrinol Metab}, volume={97}, number={4}, pages={E510-20}}"}}, {"_id": "26284586", "pmid": 26284586, "pmcid": "PMC4741856", "title": "mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib", "journal": "Oncotarget", "authors": ["Hanly EK", "Bednarczyk RB", "Tuli NY", "Moscatello AL", "Halicka HD", "Li J", "Geliebter J", "Darzynkiewicz Z", "Tiwari RK"], "date": "2015-11-24T00:00:00Z", "doi": "10.18632/oncotarget.4052", "meta_date_publication": "2015 Nov 24", "meta_volume": "6", "meta_issue": "37", "meta_pages": "39702-13", "score": 50040.758, "text_hl": "Although @CELLLINE_CVCL:1054 @@@8505c@@@ @<m>DISEASE_Thyroid_Carcinoma_Anaplastic</m> @DISEASE_MESH:D065646 @@@anaplastic thyroid cancer@@@ cells were unaffected by treatment with @CHEMICAL_Vemurafenib @CHEMICAL_MESH:D000077484 @@@vemurafenib@@@, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ alone decreased their viability significantly to 75% that of untreated. ", "citations": {"NLM": "Hanly EK, Bednarczyk RB, Tuli NY, Moscatello AL, Halicka HD, Li J, Geliebter J, Darzynkiewicz Z, Tiwari RK. mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib Oncotarget. 2015 Nov 24;6(37):39702-13. PMID: 26284586", "BibTeX": "@article{26284586, title={mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib}, author={Hanly EK and Bednarczyk RB and Tuli NY and Moscatello AL and Halicka HD and Li J and Geliebter J and Darzynkiewicz Z and Tiwari RK}, journal={Oncotarget}, volume={6}, number={37}, pages={39702-13}}"}}]}